Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue Estimates

Stock Information for Karyopharm Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Karyopharm Therapeutics Inc.

Paratek Pharmaceuticals Completes Acquisition of Optinose, Creating an Expanded Portfolio of Specialty Therapies
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders
OPTINOSE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of OptiNose, Inc. - OPTN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COOP, OPTN, AZEK, MESA on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: The AZEK Company Inc. (NYSE - AZEK), Mesa Air Group, Inc. (Nasdaq - MESA), Mr. Cooper Group Inc. (Nasdaq - COOP), Optinose, Inc. (Nasdaq - OPTN)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COOP, MESA on Behalf of Shareholders
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: The AZEK Company Inc. (NYSE - AZEK), Mesa Air Group, Inc. (Nasdaq - MESA), Mr. Cooper Group Inc. (Nasdaq - COOP), Optinose, Inc. (Nasdaq - OPTN)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, SLRN, AKYA, SHYF on Behalf of Shareholders

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.